Health Catalyst (NASDAQ:HCAT - Get Free Report) had its price target decreased by stock analysts at Wells Fargo & Company from $10.00 to $6.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has an "overweight" rating on the stock. Wells Fargo & Company's price objective would indicate a potential upside of 132.65% from the stock's current price.
Several other equities research analysts also recently weighed in on HCAT. Evercore ISI lowered their price target on Health Catalyst from $5.00 to $4.00 and set an "in-line" rating for the company in a report on Wednesday, July 9th. Stifel Nicolaus lowered their price target on Health Catalyst from $5.50 to $4.50 and set a "hold" rating for the company in a report on Friday. Cantor Fitzgerald reissued a "neutral" rating and issued a $4.00 price target (down previously from $9.00) on shares of Health Catalyst in a report on Friday. Canaccord Genuity Group lowered their price target on Health Catalyst from $10.00 to $9.00 and set a "buy" rating for the company in a report on Thursday, May 8th. Finally, KeyCorp lowered their price target on Health Catalyst from $7.00 to $5.00 and set an "overweight" rating for the company in a report on Wednesday, April 16th. Seven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat, Health Catalyst has an average rating of "Hold" and a consensus target price of $6.18.
Get Our Latest Analysis on Health Catalyst
Health Catalyst Stock Down 8.9%
NASDAQ HCAT traded down $0.25 during trading on Monday, hitting $2.58. The company's stock had a trading volume of 511,751 shares, compared to its average volume of 686,785. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.24 and a quick ratio of 1.24. The company has a market cap of $179.50 million, a PE ratio of -1.70 and a beta of 1.46. The business's 50 day simple moving average is $3.84 and its 200-day simple moving average is $4.25. Health Catalyst has a fifty-two week low of $2.52 and a fifty-two week high of $9.24.
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of HCAT. First Light Asset Management LLC lifted its holdings in Health Catalyst by 99.1% in the first quarter. First Light Asset Management LLC now owns 10,436,807 shares of the company's stock valued at $47,279,000 after acquiring an additional 5,195,686 shares during the period. Nepsis Inc. lifted its holdings in Health Catalyst by 2,072.1% in the first quarter. Nepsis Inc. now owns 2,090,812 shares of the company's stock valued at $9,471,000 after acquiring an additional 1,994,555 shares during the period. Whetstone Capital Advisors LLC acquired a new position in Health Catalyst in the first quarter valued at approximately $7,724,000. Alyeska Investment Group L.P. lifted its holdings in Health Catalyst by 74.4% in the fourth quarter. Alyeska Investment Group L.P. now owns 2,019,380 shares of the company's stock valued at $14,277,000 after acquiring an additional 861,150 shares during the period. Finally, Nuveen LLC acquired a new position in Health Catalyst in the first quarter valued at approximately $2,674,000. 85.00% of the stock is owned by institutional investors and hedge funds.
Health Catalyst Company Profile
(
Get Free Report)
Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Health Catalyst, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Health Catalyst wasn't on the list.
While Health Catalyst currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access